With an FDA decision in moderate-to-severe atopic dermatitisexpected before the end of the year, new ARCADIA data from the Maui Derm NP+PA Fall 2024 meeting is shedding further light on the effects of nemolizumab (Nemluvio) among this patient population. Click here to read more.
